search icon
search icon
Flag Arrow Down
Română
Română
Magyar
Magyar
English
English
Français
Français
Deutsch
Deutsch
Italiano
Italiano
Español
Español
Русский
Русский
日本語
日本語
中国人
中国人

Change Language

arrow down
  • Română
    Română
  • Magyar
    Magyar
  • English
    English
  • Français
    Français
  • Deutsch
    Deutsch
  • Italiano
    Italiano
  • Español
    Español
  • Русский
    Русский
  • 日本語
    日本語
  • 中国人
    中国人
Sections
  • News
  • Exclusive
  • INSCOP Surveys
  • Podcast
  • EU
  • Diaspora
  • Republic of Moldova
  • Politics
  • Economy
  • Current Affairs
  • International
  • Sport
  • Health
  • Education
  • IT&C knowledge
  • Arts & Lifestyle
  • Opinions
  • Elections 2025
  • Environment
About Us
Contact
Privacy policy
Terms and conditions
Quickly scroll through news digests and see how they are covered in different publications!
  • News
  • Exclusive
    • INSCOP Surveys
    • Podcast
    • EU
    • Diaspora
    • Republic of Moldova
    • Politics
    • Economy
    • Current Affairs
    • International
    • Sport
    • Health
    • Education
    • IT&C knowledge
    • Arts & Lifestyle
    • Opinions
    • Elections 2025
    • Environment
134 new news items in the last 24 hours
  1. Home
  2. International

The European Union has approved the Kisunla medication for the treatment of Alzheimer's disease, imposing strict conditions regarding its administration.

Matei Gaginsky
whatsapp
facebook
linkedin
x
copy-link copy-link
26 September 2025, 09:29
main event image
International
Foto: https://www.pexels.com/
google-preference

Always see our news on Google

The European Commission has approved Kisunla, a treatment for mild cognitive impairments, including dementia in the early stages of Alzheimer's disease. Although the drug, based on the molecule donanemab, has shown promising results in clinical trials, controversy remains regarding its actual benefits and the risks of serious side effects. The authorization is conditional on its administration only to patients without genetic mutations that could increase the risks. EU member states have the freedom to decide on reimbursement, and other countries, such as the United Kingdom, have adopted a similar approach.

Sources

sursa imagine
News.ro
Uniunea Europeană autorizează Kisunla, un tratament al Eli Lilly controversat împotriva maladiei Alzheimer. În afară de beneficii reale modeste, are efecte secundare grave, uneori mortale, şi anume hemoragii şi edeme cerebrale
sursa imagine
Cotidianul
UE a aprobat un nou medicament pentru Alzheimer
sursa imagine
DCNews
UE a aprobat un nou tratament controversat împotriva Alzheimer
sursa imagine
Stirile ProTV
Noi tratamente împotriva Alzheimer: UE a autorizat un medicament promițător, dar cu efecte secundare grave posibile
sursa imagine
G4Media
Noi tratamente împotriva Alzheimer: UE autorizează medicamentul Kisunla, produs de Eli Lilly
sursa imagine
Stiripesurse
Noi tratamente împotriva Alzheimer: UE autorizează medicamentul Kisunla, produs de Eli Lilly
sursa imagine
Gandul
O nouă speranță pentru pacienții cu ALZHEIMER. Comisia Europeană aprobă primul tratament care poate încetini evoluția bolii
sursa imagine
Digi24
Comisia Europeană a autorizat comercializarea unui medicament pentru tratarea bolii Alzheimer în stadii incipiente

Latest News

22:59

Traian Băsescu, critic of the political class: "When we are left without electricity, when drones are falling around us, they are getting their hair done and going to Cotroceni"

22:48

Midfielder Damjan Djokovic unilaterally terminated the contract with CFR Cluj

22:40

Trade exchanges between Romania and the USA exceeded 7.8 billion dollars in 2025

22:33

Craiova University drew 1-1 in the first leg of the Europa League play-off against Ararat-Armenia.

22:19

USA: a 35-year-old woman has been accused of supporting ISIS and planning an attack on the Congress building in New York

See more news

NEWS ON THE SAME TOPICS

event image
International
The European Medicines Agency has recommended the approval of the Wegovy tablet, a weight loss medication from Novo Nordisk.
event image
Health
France will start partial reimbursement of treatments for obesity from June, thus becoming the first state in the EU to subsidize these medications.
event image
International
AstraZeneca announced the failure of a drug for a rare heart condition, causing a 9% drop in the company's shares.
event image
International
France will start reimbursing weight loss medications from June 15, becoming the first European country to cover these treatments.
event image
EU
The European Union does not recommend entry checks for travelers returning from the Ebola outbreak area.
event image
EU
The European Commission is investigating Sanofi for the possible disparagement of a rival flu vaccine intended for vulnerable patients.
app preview
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
app preview app preview
Alzheimer's disease EU pharmaceutical industry

Editor’s Recommendations

main event image
Opinions
14 hours ago

Andrei Pleșu: About public speaking

app preview
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
app preview
app store badge google play badge
  • News
  • Exclusive
  • INSCOP Surveys
  • Podcast
  • EU
  • Diaspora
  • Republic of Moldova
  • Politics
  • Economy
  • Current Affairs
  • International
  • Sport
  • Health
  • Education
  • IT&C knowledge
  • Arts & Lifestyle
  • Opinions
  • Elections 2025
  • Environment
  • About Us
  • Contact
Privacy policy
Cookies Policy
Terms and conditions
Open source licenses
All rights reserved Strategic Media Team SRL

Technology in partnership with

anpc-sal anpc-sol